D + Q (dasatinib + quercetin) functions as a senolytic by selectively inducing apoptosis in senescent cells through dasatinib's inhibition of SRC family kinases and quercetin's broad tyrosine kinase inhibition, while simultaneously blocking anti-apoptotic pathways in cells that have exited the cell cycle. This combination targets the senescence-associated secretory phenotype (SASP) pathway, reducing chronic low-grade inflammation driven by accumulated senescent cells with age. Preclinical evidence in murine models demonstrates improved physical function, reduced frailty markers, and extended healthspan following senolytic treatment; human clinical trials remain limited, with preliminary data from small cohorts suggesting improvements in physical function and reduced senescence markers in osteoarthritis and idiopathic pulmonary fibrosis patients, though robust longevity outcomes in humans remain to be established.
Senolytics (e.g., dasatinib + quercetin, fisetin) are compounds studied for their ability to selectively eliminate senescent cells. They are not FDA-approved for any senolytic or longevity indication; dasatinib itself is approved for certain leukemias.
Early-phase human trials (e.g., Kirkland 2023, Phase II) have evaluated D+Q in small cohorts. No pooled hazard ratio for hard clinical outcomes currently exists — see the full profile for available trial-level detail.
This reflects single-trial or small pooled-trial signal in humans, per Geroevidence's four-tier methodology, rather than the larger concordant RCT base required for a Moderate or Strong classification.
Dasatinib carries known risks from its approved leukemia indication, including myelosuppression and fluid retention, typically at doses higher than senolytic protocols studied. Quercetin's safety profile as a supplement is generally considered favorable, though drug-interaction data is limited.
Both are studied as senolytics with distinct proposed mechanisms. D+Q has more published human trial data; fisetin's human evidence base is currently under editorial review on Geroevidence. See the fisetin profile for comparison.